ABUS 250117 4.00P (ABUS250117P4000) Stock Options, News & Quotes

US OptionsDetailed Quotes

ABUS250117P4000

Watchlist

0.82
0.000.00%

15min DelayClose Dec 30 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Antisense & RNAi Therapeutics Market Report 2024, Featuring Profiles of Alnylam Pharmaceuticals, Arbutus Biopharma, Benitec Biopharma, GSK, Ionis Pharmaceuticals, Sanofi, Sarepta Therapeutics & More - ResearchAndMarkets.com
BusinesswireDec 11 12:41 ET
Here's Why Arbutus (ABUS) Surged in Q3
Yahoo FinanceDec 6 08:20 ET
Whitefort Capital Sends Letter To Arbutus Biopharma Board Of Directors; Believes Now Is The Time For Arbutus To Pursue A License And Collaboration Agreement With A Strategic Partner And Explore All Options For HBV Portfolio
BenzingaDec 3 08:24 ET
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
Arbutus BiopharmaNov 26 00:00 ET
Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday
BenzingaNov 20 07:45 ET
Chardan Capital Maintains Buy on Arbutus Biopharma, Raises Price Target to $5
BenzingaNov 20 05:58 ET · Ratings

Comments

Jaguar8

Nov 15 10:05

ADDED NEWS

$Arbutus Biopharma (ABUS.US)$
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
Arbutus Biopharma (ABUS) announced promising results from its IM-PROVE I Phase 2a clinical trial for imdusiran, its RNAi therapeutic for chronic hepatitis B virus (cHBV).
When combined with 24 weeks of pegylated interferon and nucleos(t)ide analogue therapy, the treatment achieved a 50% functional cure rate (3/6 patients) in patients with baseline ...

Jaguar8

Nov 15 10:02

NEWS

$Arbutus Biopharma (ABUS.US)$
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Arbutus Biopharma and Barinthus Bio announced new preliminary data from Phase 2a IM-PROVE II trial for chronic hepatitis B treatment.
The study evaluated the combination of imdusiran, VTP-300, and low-dose nivolumab.
Key findings show that 23% of participants receiving the triple combinati...

Jaguar8

Oct 15 07:58

NEWS

$Arbutus Biopharma (ABUS.US)$
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
Arbutus Biopharma (Nasdaq: ABUS) announced that clinical data for imdusiran, an RNAi therapeutic for chronic hepatitis B virus (cHBV) infection, will be presented in four posters at the AASLD - The Liver Meeting® 2024. Two late-breaking posters will feature data from the IM-PROVE I and IM-PROVE II Phase 2a clinical trials.
Key findings fr...

Trytosaveabit

Aug 1 06:56

Update

$Arbutus Biopharma (ABUS.US)$ Trading quotes resume at 7:55 and trading at 8:00AM est

Trytosaveabit

Aug 1 06:32

News

$Arbutus Biopharma (ABUS.US)$ Reuters· 1 min ago
Arbutus Biopharma Corp: Prioritizing Imdusiran Phase 2B Clinical Development. Also planning 40% reduction in workforce